Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
Bromocriptine
Continuous glucose monitoring
Prolactinoma
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
15
07
2020
received:
27
04
2020
accepted:
16
07
2020
pubmed:
25
7
2020
medline:
1
2
2022
entrez:
25
7
2020
Statut:
ppublish
Résumé
Dopamine receptor agonists are typically used to treat Parkinson's disease and certain pituitary tumors, such as prolactinoma or a growth hormone-producing tumor. A 53-year-old woman with a history of prolactinoma was referred to Kumamoto University Hospital (Kumamoto, Japan) with poorly controlled type 2 diabetes. Her glycated hemoglobin and serum prolactin levels were increased (8.8% and 160.3 ng/mL, respectively). Bromocriptine, a dopamine D
Identifiants
pubmed: 32706496
doi: 10.1111/jdi.13369
pmc: PMC8015810
doi:
Substances chimiques
Blood Glucose
0
Dopamine Agonists
0
Bromocriptine
3A64E3G5ZO
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
668-671Informations de copyright
© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Diabetes Care. 2011 Apr;34(4):789-94
pubmed: 21447659
Prim Care Diabetes. 2016 Feb;10(1):60-5
pubmed: 26670921
Metabolism. 1991 Jun;40(6):639-44
pubmed: 1865827
Intern Med. 2019 Nov 1;58(21):3125-3128
pubmed: 31243214
Trends Endocrinol Metab. 2020 Apr;31(4):276-286
pubmed: 32044206
Neuroreport. 1997 Nov 10;8(16):3495-9
pubmed: 9427314
Neuroendocrinology. 2000 Jan;71(1):68-78
pubmed: 10644901
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Postgrad Med. 2016 Nov;128(8):828-838
pubmed: 27458683
Brain Res. 1983 Aug 29;273(2):369-73
pubmed: 6616244